Current Report · Items 2.02, 7.01, 9.01 · 8-K

Parabilis Medicines, Inc.

PBLSNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

Filed Aug 13, 2026Accepted Aug 13, 2026, 7:19 AM EDTCIK 1657677Accession 0001193125-26-347869

Company context

We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.

Current securities

PBLSNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On August 13, 2026, Parabilis Medicines, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 13, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the investor relation page of the Company’s website at https://parabilismed.com/. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information included under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by Parabilis Medicines, Inc. on August 13, 2026, furnished herewith. 99.2 Corporate Presentation of Parabilis Medicines, Inc. dated August 2026, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). .

Filed exhibits (2)

EX-99.1 (by filename) ck0001657677-ex99_1.htm

EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary HeliconTM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030 CAMBRIDGE, Mass., August 13, 2026 - Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today reported financial results and business updates for the second quarter ended June 30, 2026. “This …

Open exhibit ↗

EX-99.2 (by filename) ck0001657677-ex99_2.htm

EX-99.2 3 ck0001657677-ex99_2.htm EX-99.2 Creating Extraordinary MedicinesDrugging Previously Undruggable Intracellular Drivers of Serious Diseases August 2026 Forward-looking statements & disclaimer PARABILIS MEDICINES This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this presentation include, without limitation, statements regarding the Company's expected cash runway. Any forward-looking statements in this presentation are based on management's current expectations and beliefs, and are subject to a number of risks and uncertainties that could negatively affect the Company's business, operating results, financial condition and stock value. These forward-looking statements are not guarantees…

Open exhibit ↗